IP Library Granted Patent US 9,943,550
Granted Patent B2
US 9,943,550 · App. 14/464,147 · Granted Apr 17, 2018

Cell populations having immunoregulatory activity, method for isolation and uses

Inventors: Dirk Büscher (Madrid, ES); Manuel Angel González De La Peña (Madrid, ES); Mario Delgado Mora (Granada, ES)
Assignees: TIGENIX, S.A.U.; CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
A61K35/35A61K39/001A61K39/0008C12N5/0636C12N5/0667A61K2035/122A61K2035/124A61K2039/5156C12N2501/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,943,550
App. No.
14/464,147
Granted
Apr 17, 2018
Kind
B2
Abstract

The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-γ) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.

Claims (12)

1. A method for treating or ameliorating one or more symptoms associated with rheumatoid arthritis, in a subject suffering from rheumatoid arthritis, which comprises administering to said subject in need of such treatment a therapeutically effective amount of an isolated cell population of adipose tissue derived cells, wherein the cells of said cell population:

a) do not express markers specific for antigen-presenting cells (APC),

b) do not express indolamine 2,3-dioxygenase (IDO) constitutively,

c) express IDO upon stimulation with interferon-gamma (IFN-γ) and,

d) present capacity to be differentiated into at least two cell lineages.

2. The method of claim 1 , wherein the cell population does not present tumorigenic activity.

3. The method of claim 1 , wherein the cell population is negative for the following cell surface markers: CD11b, CD11c, CD14, CD31, CD34, CD45, CD133 and HLAII.

4. The method of claim 1 , wherein the cell population is positive for at least one of the following cell surface markers: CD9, CD44, CD54, CD90 and CD105.

5. The method of claim 1 , wherein the cell population is capable of being expanded ex vivo.

6. The method of claim 1 , wherein the cell population is from human origin.

7. The method of claim 1 , wherein said cell population is irradiated with a controlled source of ionizing radiation for an exposure time, wherein said exposure time is adjusted to impart a radiation dose that causes growth arrest of said cell population.

8. The method of claim 1 , wherein said cell population is treated with IFN-γ.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2022
From: TIGENIX, S.A.U.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 060516/0532 →
Priority Claims (1)
EP 05077186 · Sep 23, 2005 · regional
Continuity (2)
Division 12067708
Related Publication 20150224146A1 · Aug 13, 2015